Acuson’s stock falls after Q3 results

Article

Ultrasound company Acuson became the latest public company to pay the price for failing to meet Wall Street expectations. The company saw its share price shed 21% following release of flat third-quarter results and subsequent downgrades by several

Ultrasound company Acuson became the latest public company to pay the price for failing to meet Wall Street expectations. The company saw its share price shed 21% following release of flat third-quarter results and subsequent downgrades by several investment firms.

For the period (end-October), Mountain View, CA-based Acuson had revenues of $102.9 million, a 2.8% increase compared with the $100.1 million posted for the same quarter last year. Net income was $4.2 million, compared with $4.5 million reported in 1997. Earnings per share were unchanged from last year and were a penny below consensus Wall Street expectations. The news prompted the company’s stock to fall from $19.06 a share to $15 on Oct. 29, the day after the news was announced.

While pleased with growth in the firm’s U.S. and European businesses, chairman and CEO Samuel Maslak cited significant weakness in selected other international markets as adversely impacting the financial results. In recognition of continued volatility in international markets, Acuson is taking steps to adjust its business and keep expenses in line with current revenue outlook for the fourth quarter and 1999, Maslak said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.